Sumitomo Mitsui DS Asset Management Company Ltd Acquires 1,346 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,957 shares of the biopharmaceutical company’s stock after acquiring an additional 1,346 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Alnylam Pharmaceuticals were worth $3,499,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ALNY. Larson Financial Group LLC grew its position in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 73 shares during the last quarter. Park Square Financial Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $28,000. Whipplewood Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 71 shares during the period. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 69 shares during the period. Finally, OFI Invest Asset Management purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $35,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $331.94 on Friday. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. The firm has a market capitalization of $43.28 billion, a P/E ratio of -158.82 and a beta of 0.23. The business has a fifty day simple moving average of $293.35 and a two-hundred day simple moving average of $265.48. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to analysts’ expectations of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The business’s quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.16) EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ALNY. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Needham & Company LLC increased their price objective on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the company a “buy” rating in a research note on Thursday, June 26th. Wall Street Zen lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, June 14th. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a research note on Monday, March 31st. Finally, Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a “buy” rating and a $353.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $340.00.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the transaction, the chief executive officer owned 48,948 shares of the company’s stock, valued at $14,899,281.72. The trade was a 39.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.